在来自澳大利亚的克隆复合体239耐甲氧西林金黄色葡萄球菌临床菌株中，Etest法检测显示头孢洛林的体外活性降低
Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.
作者信息
Abbott I J, Jenney A W J, Jeremiah C J, Mirčeta M, Kandiah J P, Holt D C, Tong S Y C, Spelman D W
机构信息
Alfred Hospital, Melbourne, Victoria, Australia
Alfred Hospital, Melbourne, Victoria, Australia.
出版信息
Antimicrob Agents Chemother. 2015 Dec;59(12):7837-41. doi: 10.1128/AAC.02015-15. Epub 2015 Sep 21.
Abstract
A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, >1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P < 0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.
摘要
采用Etest（生物梅里埃公司）对总共421株耐甲氧西林金黄色葡萄球菌（MRSA）临床分离株进行了头孢洛林敏感性检测。发现40.9%的分离株具有多重耐药表型，33.5%的分离株属于克隆复合体239（CC239）。总体而言，头孢洛林不敏感率（MIC，>1.0μg/ml）为16.9%。与对照相比，CC239（41.1%，58/141）和具有多重耐药表型的分离株（35.5%，61/172）中的不敏感率显著更高（P<0.0001）。常见多重耐药MRSA克隆的不敏感性限制了头孢洛林在这些感染中的经验性使用。
相似文献
1
Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.
Antimicrob Agents Chemother. 2015 Dec;59(12):7837-41. doi: 10.1128/AAC.02015-15. Epub 2015 Sep 21.
2
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.
Antimicrob Agents Chemother. 2015 Dec;59(12):7873-7. doi: 10.1128/AAC.01833-15. Epub 2015 Sep 28.
3
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
Antimicrob Agents Chemother. 2012 Sep;56(9):4779-85. doi: 10.1128/AAC.00817-12. Epub 2012 Jun 25.
4
Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.
Eur J Clin Microbiol Infect Dis. 2017 Feb;36(2):343-350. doi: 10.1007/s10096-016-2807-5. Epub 2016 Oct 15.
5
In vitro activity of ceftaroline and ceftobiprole against methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin isolated in paediatric patients.
J Chemother. 2018 Oct-Dec;30(6-8):338-341. doi: 10.1080/1120009X.2018.1522473. Epub 2018 Oct 30.
6
activity of ceftaroline: A novel antibiotic against methicillin-resistant .
Indian J Pathol Microbiol. 2016 Oct-Dec;59(4):496-498. doi: 10.4103/0377-4929.191798.
7
In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.
J Med Microbiol. 2016 Oct;65(10):1119-1122. doi: 10.1099/jmm.0.000341. Epub 2016 Aug 22.
8
Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2352-8. doi: 10.1128/AAC.03006-15. Print 2016 Apr.
9
Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
J Infect Public Health. 2020 Oct;13(10):1589-1591. doi: 10.1016/j.jiph.2020.07.018. Epub 2020 Aug 26.
10
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.
Antimicrob Agents Chemother. 2015 Oct 26;60(1):343-7. doi: 10.1128/AAC.01867-15. Print 2016 Jan.
引用本文的文献
1
MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework.
Front Microbiol. 2023 Jan 10;13:1067284. doi: 10.3389/fmicb.2022.1067284. eCollection 2022.
2
Evaluation of activity of ceftaroline on methicillin resistant blood isolates from Iran.
Iran J Microbiol. 2021 Aug;13(4):442-448. doi: 10.18502/ijm.v13i4.6967.
3
Using genomics to understand meticillin- and vancomycin-resistant infections.
Microb Genom. 2020 Jan;6(1). doi: 10.1099/mgen.0.000324.
4
Antimicrobial resistance in methicillin-resistant to newer antimicrobial agents.
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01216-19. Epub 2019 Sep 16.
5
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.
Microorganisms. 2019 Aug 18;7(8):270. doi: 10.3390/microorganisms7080270.
6
CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.
Trials. 2016 Mar 31;17:170. doi: 10.1186/s13063-016-1295-3.
本文引用的文献
1
Antimicrobial susceptibility of Staphylococcus aureus and molecular epidemiology of meticillin-resistant S. aureus isolated from Australian hospital inpatients: Report from the Australian Group on Antimicrobial Resistance 2011 Staphylococcus aureus Surveillance Programme.
J Glob Antimicrob Resist. 2013 Sep;1(3):149-156. doi: 10.1016/j.jgar.2013.04.005. Epub 2013 Jun 1.
2
Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.
J Antimicrob Chemother. 2015 Dec;70(12):3259-66. doi: 10.1093/jac/dkv265. Epub 2015 Aug 27.
3
Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study.
Diagn Microbiol Infect Dis. 2015 Oct;83(2):175-82. doi: 10.1016/j.diagmicrobio.2015.06.007. Epub 2015 Jun 17.
4
Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline.
J Antimicrob Chemother. 2015 Oct;70(10):2844-53. doi: 10.1093/jac/dkv179. Epub 2015 Jul 4.
5
In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus isolates.
Indian J Med Microbiol. 2015 Jul-Sep;33(3):464-5. doi: 10.4103/0255-0857.158612.
6
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.
J Antimicrob Chemother. 2015 Sep;70(9):2488-98. doi: 10.1093/jac/dkv131. Epub 2015 Jun 4.
7
Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia.
J Antimicrob Chemother. 2015 Aug;70(8):2413-4. doi: 10.1093/jac/dkv124. Epub 2015 May 14.
8
Pre-Use Susceptibility to Ceftaroline in Clinical Staphylococcus aureus Isolates from Germany: Is There a Non-Susceptible Pool to be Selected?
PLoS One. 2015 May 8;10(5):e0125864. doi: 10.1371/journal.pone.0125864. eCollection 2015.
9
Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
J Antimicrob Chemother. 2015 Jul;70(7):2053-6. doi: 10.1093/jac/dkv076. Epub 2015 Mar 25.
10
Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2015 May;59(5):2960-3. doi: 10.1128/AAC.05004-14. Epub 2015 Mar 9.
Zotero 插件